May 19, 2021
Via: PharmaphorumIt’s not uncommon for drug developers put a positive spin on lacklustre clinical data, but CytoDyn’s attempts seems to have irritated the US regulator, specifically relating to its use of subgroup analyses to try to indicate a benefit for leronlimab. […]
July 11, 2024
July 11, 2024
July 19, 2024